Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $9.3200 (-2.41%) ($8.7500 - $9.5600) on Mon. Mar. 2, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.4% (three month average) | RSI | 34 | Latest Price | $9.3200(-2.41%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -2.3% a day on average for past five trading days. | Weekly Trend | FOLD declines -6.3% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(60%) IWO(56%) XBI(55%) IWM(53%) IWC(51%) | Factors Impacting FOLD price | FOLD will decline at least -1.7% in a week (0% probabilities). VIXM(-33%) VXX(-19%) TLT(-13%) IGOV(-6%) UNG(-1%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.7% (StdDev 3.4%) | Hourly BBV | 0 () | Intraday Trend | -1.9% | | | |
|
Resistance Level | $10.3 | 5 Day Moving Average | $9.57(-2.61%) | 10 Day Moving Average | $10.11(-7.81%) | 20 Day Moving Average | $10.3(-9.51%) | To recent high | -16.5% | To recent low | 5.4% | Market Cap | $2.407b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |